Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 3/20 | 0.56 |
| ▸ | ITGA4 | P13612 | 17/20 | 0.54 |
| ▸ | ITGB1 | P05556 | 16/20 | 0.54 |
| ▸ | ITGB7 | P26010 | 13/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5783352 | 0.91 | ITGA4 (0.51) | CDK2ITGA4ITGB1ITGB7 | |
| SCHEMBL5784145 | 0.89 | ATM (0.55) | CDK2ITGA4ITGB1ITGB7 | |
| SCHEMBL5786791 | 0.89 | ITGA4 (0.63) | ITGA4ITGB1ITGB7 | |
| SCHEMBL5786480 | 0.87 | ITGA4 (0.53) | CDK2ITGA4ITGB1ITGB7 | |
| SCHEMBL5783839 | 0.87 | ITGA4 (0.52) | CDK2ITGA4ITGB1ITGB7 | |
| SCHEMBL6507799 | 0.87 | ITGA4 (0.51) | CDK2ITGA4ITGB1ITGB7 | |
| SCHEMBL5785648 | 0.86 | ITGA4 (0.53) | CDK2ITGA4ITGB1ITGB7 | |
| SCHEMBL5784049 | 0.86 | ITGA4 (0.57) | ITGA4ITGB1ITGB7 | |
| SCHEMBL5784760 | 0.86 | ITGA4 (0.57) | ITGA4ITGB1ITGB7 | |
| SCHEMBL297398 | 0.85 | ATM (0.61) | ITGA4ITGB1ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1049662-B1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2006-06-21 | — | — | EP | disclosed |
| US-6855843-B2 | Inhibitors of α4 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2005-02-15 | — | — | US | disclosed |
| US-20030191118-A1 | Inhibitors of alpha4 mediated cell adhesion | TANABE SEIYAKU CO., LTD. | 2003-10-09 | — | — | US | disclosed |
| US-6521666-B1 | Inhibitors of α4 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2003-02-18 | — | — | US | disclosed |
| EP-1049662-A1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999036393-A1 | INHIBITORS OF α4 MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 1999-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191118-A1 | Inhibitors of alpha4 mediated cell adhesion | ITGB4, ITGA4, VCAM1 | CDK2 1694/4885ITGA4 2/4885ITGB1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.